ARTICLE | Company News
Takeda grants newco Izana rights to autoimmune candidate
December 15, 2017 9:42 PM UTC
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) granted newco Izana Bioscience (London, UK) exclusive, worldwide rights to develop and commercialize namilumab (MT203, IZN-101). Takeda will receive an undisclosed equity stake in the newco. Next half, Izana plans to begin a Phase II trial of namilumab to treat ankylosing spondylitis.
Izana also received a £1.4 million ($1.9 million) grant from Innovate UK to support the trial...
BCIQ Target Profiles
Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)